Summary
Chong Kim is a director-level health economist and data scientist with 9 years of experience building statistical methods, observational studies, and reproducible analytics to improve global healthcare decision-making. He combines deep academic training (PhD in pharmacoeconomics and MS in biostatistics) with industry leadership at Gilead and Stratevi, delivering cost-effectiveness analyses, risk-adjustment models, and software workflows that support high-stakes health technology assessments. Known for pragmatic problem-solving, Chong bridges methodological innovation (R/Python tool development and causal inference) with operational impact across HEOR, ICER-style CEAs, and real-world evidence projects. He brings a rare blend of bench science origins and quantitative health policy expertise, having worked on everything from smart inhaler economic models to spatial analyses of malaria interventions.
10 years of coding experience
8 years of employment as a software developer
Doctor of Philosophy (Ph.D.) Pharmacoeconomics/Pharmaceutical Economics, Doctor of Philosophy (Ph.D.) Pharmacoeconomics/Pharmaceutical Economics at University of Colorado Anschutz Medical Campus
Master of Public Health (MPH) Health Policy & Management & Comparative Effectiveness Outcomes Research, Master of Public Health (MPH) Health Policy & Management & Comparative Effectiveness Outcomes Research at Columbia University Mailman School of Public Health
B.S. Biochemistry & Molecular Biology, B.S. Biochemistry & Molecular Biology at Michigan State University
Spanish, Korean